title: Effects of G.H.3. On mental symptoms and health-related quality of life among older adults: results of a three-month follow-Up study in Shanghai, China.
abstract: OBJECTIVE
  To explore the effects of daily use of Gerovital H3 (G.H.3.) tablets on relieving mental symptoms and improving health-related quality of life among Chinese older adults population.
  
  
  METHODS
  In a randomized, placebo-controlled, double-blinded study, totally 100 eligible participants were randomly allocated into the G.H.3. group or the placebo group, administered either G.H.3. or placebo tablets and were followed up for three months. All of the participants were required to report their subjective feelings about quality of life, low mood, and anxiety by filling out Self-Rating Depression Scale (SDS), Self-Rating Anxiety Scale (SAS) and a 36-item Short-Form Health Survey (SF-36 scale). Physicians were responsible for evaluating the related mental health indications through physical examinations at the baseline and at the end of the intervention period.
  
  
  RESULTS
  Participants were men and women between 50 and 89 years of age, with a median of 62.53 years. Before the intervention, the demographic characteristics and the baseline SF-36 scores, low mood, and anxiety statuses were comparable (p > 0.05). After the 12-week intervention, the scores of role-physical (RP), bodily pain (BP), general health (GH), vitality (VT), mental health (MH) and health transition (HT), mental composite score (MCS) of the G.H.3. group were higher than the placebo group (p < 0.05), There were no significant differences in other domains in SF-36 and PCS between the two groups(p > 0.05), the scores of SDS and SAS in the G.H.3. group were both lower than the placebo group(p < 0.01), the prevalence rates of low moods in the G.H.3. group and the placebo group were 20.8 % and 34.0 % respectively, no significant difference was found (χ (2) =2.127,p = 0.145), while the prevalence rate of clinical anxiety concerns in the G.H.3. group was 2.1 %, which was significantly lower than the placebo group, 22.0 % (χ (2) =9.040,p < 0.001).
  
  
  CONCLUSIONS
  Preliminarily use of G.H.3. shows positive effects in supporting mental health and improving general health and well-being while promoting the recovery of cognitive function among older adults. Most of SF-36 domains including PF, RP, BP, GH, VT, RE, MH, and HT, as well as the overall quality of life in MCS might benefit from taking G.H.3. tablets. Average levels of low moods and anxiety concerns were both reduced and the prevalence rate of clinical anxiety concerns were reduced.
authors.affiliation: School of Public Health, Shanghai Jiaotong University, Shanghai, China.
authors.forename: Gang
authors.initials: G
authors.lastname: Xu
authors.affiliation: Jiaxing Community Health Service Center, Hongkou District, Shanghai, China.
authors.forename: Zhaochun
authors.initials: Z
authors.lastname: Cao
authors.affiliation: Department of Research, DRM Resources, 1683, Sunflower Avenue, Costa Mesa, CA, 92626, USA.
authors.forename: Mina
authors.initials: M
authors.lastname: Shariff
authors.affiliation: Department of Research, DRM Resources, 1683, Sunflower Avenue, Costa Mesa, CA, 92626, USA.
authors.forename: Pingping
authors.initials: P
authors.lastname: Gu
authors.affiliation: Department of Research, DRM Resources, 1683, Sunflower Avenue, Costa Mesa, CA, 92626, USA.
authors.forename: Tuong
authors.initials: T
authors.lastname: Nguyen
authors.affiliation: Beijing University of Chinese Medicine, Beijing, China.
authors.forename: Tian
authors.initials: T
authors.lastname: Zhou
authors.affiliation: School of Public Health, Shanghai Jiaotong University, Shanghai, China. shirong61@163.com.
authors.forename: Rong
authors.initials: R
authors.lastname: Shi
authors.affiliation: Department of Pathology and Laboratory Medicine, in UCLA Medical Center, University of California, Los Angeles, CA, USA. jrao@mednet.ucla.edu.
authors.forename: Jianyu
authors.initials: J
authors.lastname: Rao
mesh_terms: D000339:Affect / Q000187:drug effects; D000368:Aged; D000369:Aged, 80 and over; D001007:Anxiety / Q000188:drug therapy; D002681:China; D019587:Dietary Supplements; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008603:Mental Health; D008875:Middle Aged; D011343:Procaine / Q000494:pharmacology*; D011788:Quality of Life; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: C004936:Gerovital H3; D011343:Procaine
references.citation: Arch Gerontol Geriatr. 2012 Nov-Dec;55(3):560-3
references.pmid: 22749403
references.citation: Psychiatr Danub. 2015 Jun;27(2):174-9
references.pmid: 26057313
references.citation: Clin Exp Hypertens. 2016;38(1):51-5
references.pmid: 26268738
references.citation: J Hum Hypertens. 2013 Mar;27(3):187-90
references.pmid: 22592133
references.citation: J Med Life. 2011 Nov 14;4(4):412-6
references.pmid: 22514575
references.citation: West Indian Med J. 2013 Sep;62(7):615-9
references.pmid: 24831899
references.citation: World J Gastroenterol. 2015 Apr 14;21(14):4302-9
references.pmid: 25892882
references.citation: Zhonghua Liu Xing Bing Xue Za Zhi. 2015 Jun;36(6):612-6
references.pmid: 26564635
references.citation: Fam Pract. 1998 Feb;15(1):67-75
references.pmid: 9527300
references.citation: J Anxiety Disord. 2006;20(5):543-61
references.pmid: 16198532
references.citation: J Geriatr Psychiatry Neurol. 1994 Oct-Dec;7(4):216-20
references.pmid: 7826489
references.citation: Clin Geriatr Med. 2007 May;23(2):327-49, vi
references.pmid: 17462520
references.citation: Arch Gerontol Geriatr. 2015 Mar-Apr;60(2):311-6
references.pmid: 25547994
references.citation: J Inherit Metab Dis. 2016 Mar;39(2):253-60
references.pmid: 26531313
references.citation: PLoS One. 2015 Mar 19;10(3):e0120234
references.pmid: 25789850
references.citation: Can J Psychiatry. 2011 Jul;56(7):387-97
references.pmid: 21835102
references.citation: Int J Clin Pharmacol Ther. 2006 Jul;44(7):335-42
references.pmid: 16961163
references.citation: Hum Brain Mapp. 2014 Sep;35(9):4488-98
references.pmid: 24578157
references.citation: Rev Bras Enferm. 2014 Nov-Dec;67(6):913-9
references.pmid: 25590881